{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:21:25Z","timestamp":1790882485990,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1053\/j.seminhematol.2022.10.002","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T22:10:34Z","timestamp":1668204634000},"page":"198-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Extranodal natural killer\/T-cell lymphoma: An overview on pathology and clinical management"],"prefix":"10.1053","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-4722","authenticated-orcid":false,"given":"Eric","family":"Tse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.seminhematol.2022.10.002_bib0001","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/000348944905800405","article-title":"Lethal granulomatous ulceration involving the midline facial tissues","volume":"58","author":"Williams","year":"1949","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"5","key":"10.1053\/j.seminhematol.2022.10.002_bib0002","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00007611-195805000-00008","article-title":"Lymphoma as a cause of lethal midline granuloma","volume":"51","author":"Baker","year":"1958","journal-title":"South Med J"},{"issue":"5","key":"10.1053\/j.seminhematol.2022.10.002_bib0003","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.10.002_bib0004","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/cancers14030597","article-title":"Recent advances in the diagnosis and treatment of natural killer cell malignancies","volume":"14","author":"Tse","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminhematol.2022.10.002_bib0005","series-title":"WHO classification of tumours of haematopoietic and lymphoid Tissues","first-page":"368","article-title":"Extranodal NK\/T-cell lymphoma, nasal type","author":"Chan","year":"2017"},{"issue":"23","key":"10.1053\/j.seminhematol.2022.10.002_bib0006","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminhematol.2022.10.002_bib0007","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1002\/cncr.30697","article-title":"The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-cell lymphoma, nasal type, in the United States","volume":"123","author":"Vargo","year":"2017","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2022.10.002_bib0008","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"353","article-title":"Aggressive NK-cell leukaemia","author":"Chan","year":"2017"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.10.002_bib0009","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.hoc.2020.01.002","article-title":"Molecular features of blastic plasmacytoid dendritic cell neoplasm: DNA mutations and epigenetics","volume":"34","author":"Sapienza","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"25","key":"10.1053\/j.seminhematol.2022.10.002_bib0010","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1182\/blood-2010-06-290650","article-title":"Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation","volume":"116","author":"Takeuchi","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2022.10.002_bib0011","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood-2010-08-302737","article-title":"NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series","volume":"117","author":"Mansoor","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.10.002_bib0012","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.beha.2019.06.006","article-title":"T cell large granular lymphocyte leukemia and chronic NK lymphocytosis","volume":"32","author":"Baril\u00e0","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0013","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/PAS.0000000000000735","article-title":"EBV-negative Aggressive NK-cell Leukemia\/Lymphoma: clinical, pathologic, and genetic features","volume":"41","author":"Nicolae","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1053\/j.seminhematol.2022.10.002_bib0014","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(16)30148-6","article-title":"Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study","volume":"17","author":"Li","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.10.002_bib0015","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1470-2045(19)30799-5","article-title":"Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations","volume":"21","author":"Lin","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2022.10.002_bib0016","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1746-1596-7-178","article-title":"LMP1 and LMP2A are potential prognostic markers of extranodal NK\/T-cell lymphoma, nasal type (ENKTL)","volume":"7","author":"Mao","year":"2012","journal-title":"Diagn Pathol"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.10.002_bib0017","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in Epstein-Barr virus-associated oncogenesis","volume":"17","author":"M\u00fcnz","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"10.1053\/j.seminhematol.2022.10.002_bib0018","article-title":"The oncogenic role of miR-BART19-3p in Epstein-Barr virus-associated diseases","volume":"2020","author":"Zhang","year":"2020","journal-title":"Biomed Res Int"},{"issue":"42","key":"10.1053\/j.seminhematol.2022.10.002_bib0019","doi-asserted-by":"crossref","first-page":"E6467","DOI":"10.1073\/pnas.1605884113","article-title":"Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells","volume":"113","author":"Albanese","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.10.002_bib0020","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3390\/v12111222","article-title":"The role of EBV-induced hypermethylation in gastric cancer tumorigenesis","volume":"12","author":"Stanland","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0021","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41392-021-00702-4","article-title":"Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma","volume":"6","author":"Xie","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.10.002_bib0022","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","article-title":"Defective Epstein-Barr virus in chronic active infection and haematological malignancy","volume":"4","author":"Okuno","year":"2019","journal-title":"Nat Microbiol"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.10.002_bib0023","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1046\/j.1365-2141.1997.3223139.x","article-title":"Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma\/leukaemia","volume":"98","author":"Wong","year":"1997","journal-title":"Br J Haematol"},{"issue":"3-4","key":"10.1053\/j.seminhematol.2022.10.002_bib0024","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/10428199909050949","article-title":"Cytogenetic abnormalities in natural killer cell lymphoma\/leukaemia\u2013is there a consistent pattern?","volume":"34","author":"Wong","year":"1999","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.10.002_bib0025","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","article-title":"Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type","volume":"115","author":"Huang","year":"2010","journal-title":"Blood"},{"issue":"50","key":"10.1053\/j.seminhematol.2022.10.002_bib0026","doi-asserted-by":"crossref","first-page":"20119","DOI":"10.1073\/pnas.1115128108","article-title":"PRDM1 is a tumor suppressor gene in natural killer cell malignancies","volume":"108","author":"K\u00fc\u00e7\u00fck","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1053\/j.seminhematol.2022.10.002_bib0027","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2011-04-346890","article-title":"Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses","volume":"118","author":"Karube","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2022.10.002_bib0028","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2014-07-588970","article-title":"Receptor-type tyrosine-protein phosphatase \u03ba directly targets STAT3 activation for tumor suppression in nasal NK\/T-cell lymphoma","volume":"125","author":"Chen","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2022.10.002_bib0029","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2022.10.002_bib0030","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1038\/leu.2017.40","article-title":"RUNX3 is oncogenic in natural killer\/T-cell lymphoma and is transcriptionally regulated by MYC","volume":"31","author":"Selvarajan","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.10.002_bib0031","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.2823","article-title":"Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK\/T cell lymphoma revealed by gene expression profiling","volume":"223","author":"Ng","year":"2011","journal-title":"J Pathol"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.10.002_bib0032","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.blre.2015.08.003","article-title":"Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?","volume":"30","author":"Iqbal","year":"2016","journal-title":"Blood Rev"},{"issue":"7","key":"10.1053\/j.seminhematol.2022.10.002_bib0033","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","article-title":"Janus kinase 3-activating mutations identified in natural killer\/T-cell lymphoma","volume":"2","author":"Koo","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2022.10.002_bib0034","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from \u03b3\u03b4-T or NK cells","volume":"6","author":"K\u00fc\u00e7\u00fck","year":"2015","journal-title":"Nat Commun"},{"issue":"19","key":"10.1053\/j.seminhematol.2022.10.002_bib0035","doi-asserted-by":"crossref","first-page":"17764","DOI":"10.18632\/oncotarget.3776","article-title":"Genetic alterations of JAK\/STAT cascade and histone modification in extranodal NK\/T-cell lymphoma nasal type","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1053\/j.seminhematol.2022.10.002_bib0036","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ng.3358","article-title":"Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma","volume":"47","author":"Jiang","year":"2015","journal-title":"Nat Genet"},{"issue":"7","key":"10.1053\/j.seminhematol.2022.10.002_bib0037","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-14-1216","article-title":"Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma","volume":"21","author":"K\u00fc\u00e7\u00fck","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1053\/j.seminhematol.2022.10.002_bib0038","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1182\/blood-2011-07-364224","article-title":"Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer\/T-cell lymphoma","volume":"118","author":"Ng","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2022.10.002_bib0039","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.10.002_bib0040","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/17474086.2019.1660640","article-title":"Recent advances in the diagnosis and treatment of natural killer\/T-cell lymphomas","volume":"12","author":"Tse","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0041","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 is upregulated by EBV-driven LMP1 through NF-\u03baB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.10.002_bib0042","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.10.002_bib0043","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.10.002_bib0044","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","article-title":"Genomic and transcriptomic characterization of natural killer T cell lymphoma","volume":"37","author":"Xiong","year":"2020","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.10.002_bib0045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41379-019-0392-8","article-title":"Immune subtyping of extranodal NK\/T-cell lymphoma: a new biomarker and an immune shift during disease progression","volume":"33","author":"Cho","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1053\/j.seminhematol.2022.10.002_bib0046","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.10.011","article-title":"A phase II study of methotrexate, etoposide, dexamethasone and pegaspargase sandwiched with radiotherapy in the treatment of newly diagnosed, stage IE to IIE extranodal natural-killer\/T-cell lymphoma, nasal-type","volume":"25","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1053\/j.seminhematol.2022.10.002_bib0047","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.2147\/OTT.S155930","article-title":"Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer\/T-cell lymphoma in vivo and in vitro","volume":"11","author":"Liu","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1053\/j.seminhematol.2022.10.002_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103614","article-title":"SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential","volume":"72","author":"Xiong","year":"2021","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.10.002_bib0049","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2967\/jnumed.113.131946","article-title":"Midtreatment \u00b9\u2078F-FDG PET\/CT scan for early response assessment of SMILE therapy in natural killer\/T-cell lymphoma: a prospective study from a single center","volume":"55","author":"Khong","year":"2014","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2022.10.002_bib0050","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/RLU.0b013e3181e4dcbf","article-title":"Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas","volume":"35","author":"Chan","year":"2010","journal-title":"Clin Nucl Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.10.002_bib0051","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-008-0562-0","article-title":"Non-nasal natural killer cell lymphoma: not non-nasal after all","volume":"88","author":"Tse","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2022.10.002_bib0052","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fonc.2019.00062","article-title":"EBV viral loads in diagnosis, monitoring, and response assessment","volume":"9","author":"Kimura","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0053","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2003-12-4197","article-title":"Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients","volume":"104","author":"Au","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.10.002_bib0054","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/leu.2013.212","article-title":"Quantification of circulating Epstein-Barr virus DNA in NK\/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance","volume":"28","author":"Kwong","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0055","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2003-05-1401","article-title":"Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index","volume":"103","author":"Chim","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2022.10.002_bib0056","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","article-title":"Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.10.002_bib0057","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1470-2045(15)00533-1","article-title":"A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0058","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41375-020-0791-3","article-title":"Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK\/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making","volume":"35","author":"Chen","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2022.10.002_bib0059","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.V89.8.2966","article-title":"CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance","volume":"89","author":"Dr\u00e9nou","year":"1997","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2022.10.002_bib0060","first-page":"4775","article-title":"BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T\/NK-cell lymphoma","volume":"4","author":"Sejic","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.10.002_bib0061","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/bjh.17951","article-title":"Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline","volume":"196","author":"Fox","year":"2022","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2022.10.002_bib0062","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study","volume":"126","author":"Yang","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.10.002_bib0063","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2141.2005.05694.x","article-title":"Selective apoptosis of natural killer-cell tumours by l-asparaginase","volume":"130","author":"Ando","year":"2005","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2022.10.002_bib0064","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s00277-022-04892-x","article-title":"Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK\/T-cell lymphoma","volume":"101","author":"Qi","year":"2022","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2022.10.002_bib0065","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/blood-2015-07-655191","article-title":"Nasal NK\/T-cell lymphoma: RT, CT, or both","volume":"126","author":"Tse","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0066","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/annonc\/mdx684","article-title":"Sequential chemotherapy\/radiotherapy was comparable with concurrent chemoradiotherapy for stage I\/II NK\/T-cell lymphoma","volume":"29","author":"Kwong","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2022.10.002_bib0067","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1002\/cam4.1755","article-title":"Promising clinical outcomes of sequential and \"Sandwich\" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I(E) \/II(E) extranodal natural killer\/T-cell lymphoma","volume":"7","author":"Wang","year":"2018","journal-title":"Cancer Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.10.002_bib0068","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1080\/10428194.2019.1599111","article-title":"Upfront radiation is essential for high-risk early-stage extranodal NK\/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era","volume":"60","author":"Qi","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0069","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijrobp.2007.05.073","article-title":"Early or up-front radiotherapy improved survival of localized extranodal NK\/T-cell lymphoma, nasal-type in the upper aerodigestive tract","volume":"70","author":"Huang","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminhematol.2022.10.002_bib0070","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.2147\/OTT.S116591","article-title":"Radiation dose reduction for patients with extranodal NK\/T-cell lymphoma with complete response after initial induction chemotherapy","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"33","key":"10.1053\/j.seminhematol.2022.10.002_bib0071","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1200\/JCO.2009.23.8295","article-title":"Phase I\/II study of concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211","volume":"27","author":"Yamaguchi","year":"2009","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1053\/j.seminhematol.2022.10.002_bib0072","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"issue":"51","key":"10.1053\/j.seminhematol.2022.10.002_bib0073","doi-asserted-by":"crossref","first-page":"85584","DOI":"10.18632\/oncotarget.11319","article-title":"Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I\/II extranodal NK\/T-cell lymphoma, nasal type (CISL-1008)","volume":"7","author":"Yoon","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.10.002_bib0074","doi-asserted-by":"crossref","first-page":"e1725","DOI":"10.1634\/theoncologist.2020-0144","article-title":"Pegaspargase combined with concurrent radiotherapy for early-stage extranodal natural killer\/T-cell lymphoma, nasal type: a two-center phase II study","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"issue":"14","key":"10.1053\/j.seminhematol.2022.10.002_bib0075","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1080\/10428194.2020.1811864","article-title":"Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population","volume":"61","author":"Ghione","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1053\/j.seminhematol.2022.10.002_bib0076","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3109\/10428194.2015.1108415","article-title":"Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK\/T-cell lymphoma","volume":"57","author":"Dong","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.10.002_bib0077","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cncr.27752","article-title":"First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE\/IIE extranodal natural killer\/T-cell lymphoma","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"issue":"30","key":"10.1053\/j.seminhematol.2022.10.002_bib0078","doi-asserted-by":"crossref","first-page":"50155","DOI":"10.18632\/oncotarget.16334","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.10.002_bib0079","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/cncr.11908","article-title":"Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer\/T-cell or T-cell lymphoma","volume":"100","author":"Li","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2022.10.002_bib0080","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","article-title":"Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia","volume":"99","author":"Yamaguchi","year":"2008","journal-title":"Cancer Sci"},{"issue":"33","key":"10.1053\/j.seminhematol.2022.10.002_bib0081","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2022.10.002_bib0082","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2022.10.002_bib0083","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaoncol.2022.1968","article-title":"Efficacy and safety of a pegasparaginase-based chemotherapy regimen vs an L-asparaginase-based chemotherapy regimen for newly diagnosed advanced extranodal natural killer\/T-cell lymphoma: a randomized clinical trial","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.10.002_bib0084","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2022.10.002_bib0085","doi-asserted-by":"crossref","first-page":"29092","DOI":"10.18632\/oncotarget.8647","article-title":"Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed\/refractory extranodal NK\/T-cell lymphoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.10.002_bib0086","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/bmt.2016.6","article-title":"Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL","volume":"51","author":"Lim","year":"2016","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"10.1053\/j.seminhematol.2022.10.002_bib0087","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.bbmt.2015.05.003","article-title":"Clinical outcomes and prognostic factors of up-front autologous stem cell transplantation in patients with extranodal natural killer\/T cell lymphoma","volume":"21","author":"Yhim","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"10.1053\/j.seminhematol.2022.10.002_bib0088","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.3109\/10428194.2015.1037764","article-title":"High-dose therapy and autologous stem cell transplantation for extra-nodal NK\/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation","volume":"56","author":"Fox","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1053\/j.seminhematol.2022.10.002_bib0089","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bbmt.2008.09.014","article-title":"Autologous hematopoietic stem cell transplantation in extranodal natural killer\/T cell lymphoma: a multinational, multicenter, matched controlled study","volume":"14","author":"Lee","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.10.002_bib0090","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.14879","article-title":"Allogeneic haematopoietic cell transplantation for extranodal natural killer\/T-cell lymphoma, nasal type: a CIBMTR analysis","volume":"182","author":"Kanate","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2022.10.002_bib0091","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/bmt.2014.65","article-title":"Allogeneic haematopoietic SCT for natural killer\/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group","volume":"49","author":"Tse","year":"2014","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"10.1053\/j.seminhematol.2022.10.002_bib0092","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/sj.leu.2403955","article-title":"Natural killer-cell malignancies: diagnosis and treatment","volume":"19","author":"Kwong","year":"2005","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2022.10.002_bib0093","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00277-021-04558-0","article-title":"Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK\/T lymphoma: results of a multicenter study","volume":"100","author":"Kim","year":"2021","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2022.10.002_bib0094","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","article-title":"Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK\/T cell lymphoma is associated with better prognosis","volume":"469","author":"Kim","year":"2016","journal-title":"Virchows Arch"},{"issue":"12","key":"10.1053\/j.seminhematol.2022.10.002_bib0095","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/s41375-020-1000-0","article-title":"Whole-genome sequencing identifies responders to Pembrolizumab in relapse\/refractory natural-killer\/T cell lymphoma","volume":"34","author":"Lim","year":"2020","journal-title":"Leukemia"},{"issue":"17","key":"10.1053\/j.seminhematol.2022.10.002_bib0096","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2022.10.002_bib0097","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2019-121865","article-title":"Preliminary results from a multicenter, single-arm, phase 2 study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with relapsed or refractory extranodal natural killer\/T cell lymphoma (rr-ENKTL)","volume":"134","author":"Huang","year":"2019","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2022.10.002_bib0098","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0099","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.10.002_bib0100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4143\/crt.2018.191","article-title":"Comparison of efficacy of pembrolizumab between epstein-barr virus\u2012positive and \u2012negative relapsed or refractory non-hodgkin lymphomas","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0101","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","article-title":"PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: efficacy and safety","volume":"97","author":"Chan","year":"2018","journal-title":"Ann Hematol"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2022.10.002_bib0102","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2019.37.15_suppl.7504","article-title":"Sintilimab for relapsed\/refractory (r\/r) extranodal NK\/T-cell lymphoma (ENKTL): a multicenter, single-arm, phase 2 trial (ORIENT-4)","volume":"37","author":"Tao","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2022.10.002_bib0103","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1200\/JCO.2022.40.16_suppl.7552","article-title":"Tislelizumab, a PD-1 inhibitor for relapsed\/refractory mature T\/NK-cell neoplasms: results from a phase 2 study","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2022.10.002_bib0104","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-015-2359-2","article-title":"CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK\/T cell lymphoma, nasal type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-020-01020-y","article-title":"Daratumumab monotherapy for patients with relapsed or refractory natural killer\/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study","volume":"14","author":"Huang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2022.10.002_bib0106","first-page":"2814","article-title":"Daratumumab efficiently targets NK\/T cell lymphoma with high CD38 expression","volume":"130","author":"Mustafa","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2022.10.002_bib0107","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.3109\/10428194.2014.974048","article-title":"Prognostic implications of CD30 expression in extranodal natural killer\/T-cell lymphoma according to treatment modalities","volume":"56","author":"Kim","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0108","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40880-017-0212-9","article-title":"CD30 expression in extranodal natural killer\/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China","volume":"36","author":"Feng","year":"2017","journal-title":"Chin J Cancer"},{"issue":"2","key":"10.1053\/j.seminhematol.2022.10.002_bib0109","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4143\/crt.2019.198","article-title":"Efficacy of Brentuximab Vedotin in relapsed or refractory high-CD30-expressing non-hodgkin lymphomas: results of a multicenter, open-labeled phase II trial","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"5","key":"10.1053\/j.seminhematol.2022.10.002_bib0110","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12185-012-1174-y","article-title":"Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE\/IIE extranodal natural killer\/T cell lymphoma, nasal type: 13-year follow-up in 135 patients","volume":"96","author":"Wang","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2022.10.002_bib0111","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-6-44","article-title":"A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK\/T-cell lymphoma, nasal type","volume":"6","author":"Lin","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"13","key":"10.1053\/j.seminhematol.2022.10.002_bib0112","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1002\/cncr.26629","article-title":"Phase 2 trial of \"sandwich\" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer\/T-cell lymphoma","volume":"118","author":"Jiang","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"10.1053\/j.seminhematol.2022.10.002_bib0113","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00277-014-2137-6","article-title":"Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK\/T cell lymphoma: CISL08-01 phase II study","volume":"93","author":"Kim","year":"2014","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2022.10.002_bib0114","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2015.07.2267","article-title":"Concurrent chemoradiation therapy followed by consolidation chemotherapy for localized extranodal natural killer\/T-cell lymphoma, nasal type","volume":"93","author":"Oh","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1053\/j.seminhematol.2022.10.002_bib0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-014-2171-4","article-title":"Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer\/T-cell lymphoma patients","volume":"94","author":"Kim","year":"2015","journal-title":"Ann Hematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196322000567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196322000567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:06Z","timestamp":1758522486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196322000567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":115,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0037196322000567"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2022.10.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extranodal natural killer\/T-cell lymphoma: An overview on pathology and clinical management","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2022.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}